Yahoo Finance CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
In the latest market close, CRISPR Therapeutics AG (CRSP) reached $65.19, with a +1.72% movement compared to the previous day. This change outpaced the S&P 500's 0.15% gain on the day. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.32%.
The company's shares have seen a decrease of 16.57% over the last month, not keeping up with the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65%.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.63, down 143.28% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.31 million, down 91.69% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$6.24 per share and revenue of $105.41 million, indicating changes of -221.65% and -71.6%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 83, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
